Edgewise Therapeutics, Inc. (EWTX)
USD 30.01
(-0.53%)
USD 30.01
(-0.53%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | 1.73 Million | 538 Thousand | 272 Thousand | 185 Thousand | 123 Thousand |
| Gross Profit | -1.73 Million | -538 Thousand | -272 Thousand | -185 Thousand | -123 Thousand |
| Operating Expenses | 114.35 Million | 22.07 Million | 43.21 Million | 17.19 Million | 9.92 Million |
| Selling, General and Administrative Expenses | 23.45 Million | 5.46 Million | 11.02 Million | 2.2 Million | 1.3 Million |
| Research and Development Expenses | 90.9 Million | 16.61 Million | 32.18 Million | 14.98 Million | 8.62 Million |
| Other Expenses | - | - | - | - | - |
| Cost and Expenses | 114.35 Million | 22.07 Million | 43.21 Million | 17.19 Million | 9.92 Million |
| Operating Income | -114.35 Million | -22.07 Million | -43.21 Million | -17.19 Million | -9.92 Million |
| Interest Expense | - | 4.01 Million | - | - | - |
| Income Tax Expense | - | -4.01 Million | -674 Thousand | -69 Thousand | -219 Thousand |
| Earnings before Tax | -100.16 Million | -19.41 Million | -42.81 Million | -17.12 Million | -9.7 Million |
| Net Income | -100.16 Million | -15.39 Million | -42.13 Million | -17.05 Million | -9.48 Million |
| Earnings Per Share Basic | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| Earnings Per Share Diluted | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| Weighted Average Shares Outstanding | 63.72 Million | 53.59 Million | 49.5 Million | 49.21 Million | 49.21 Million |
| Weighted Average Shares Outstanding (Diluted) | 63.72 Million | 53.59 Million | 49.5 Million | 49.21 Million | 49.21 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -112.8 Million | -67.1 Million | -42.94 Million | -17 Million | -9.8 Million |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 2.25 Million | - | - | - |
| Cost of Revenue | 534 Thousand | 525 Thousand | 533 Thousand | 1.73 Million | 448 Thousand | 437 Thousand |
| Gross Profit | -534 Thousand | -525 Thousand | 1.71 Million | -1.73 Million | -448 Thousand | -437 Thousand |
| Operating Expenses | 37.57 Million | 34.22 Million | 33.86 Million | 112.62 Million | 29.45 Million | 25.33 Million |
| Selling, General and Administrative Expenses | 7.37 Million | 7 Million | 6.17 Million | - | 5.66 Million | 5.78 Million |
| Research and Development Expenses | 30.2 Million | 27.22 Million | 27.68 Million | - | 23.78 Million | 19.55 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 38.1 Million | 34.75 Million | 33.86 Million | 114.35 Million | 29.45 Million | 25.33 Million |
| Operating Income | -38.1 Million | -34.75 Million | -33.86 Million | -114.35 Million | -29.45 Million | -25.33 Million |
| Interest Expense | - | - | 3.1 Million | - | - | - |
| Income Tax Expense | - | 481.72 Thousand | 3.6 Million | - | -497 Thousand | 338.91 Thousand |
| Earnings before Tax | -31.49 Million | -28.52 Million | -30.14 Million | -100.16 Million | -25.71 Million | -21.46 Million |
| Net Income | -31.49 Million | -28.52 Million | -30.14 Million | -100.16 Million | -25.71 Million | -21.46 Million |
| Earnings Per Share Basic | -0.34 | -0.33 | -0.47 | - | -0.41 | -0.34 |
| Earnings Per Share Diluted | -0.34 | -0.33 | -0.47 | - | -0.41 | -0.34 |
| Weighted Average Shares Outstanding | 93.51 Million | 87.56 Million | 64.77 Million | 63.72 Million | 63.45 Million | 63.38 Million |
| Weighted Average Shares Outstanding (Diluted) | 93.51 Million | 87.56 Million | 64.77 Million | 63.72 Million | 63.45 Million | 63.38 Million |
| Gross Margin | - | - | 0.76 | - | - | - |
| EBIT Margin | - | - | -14.80 | - | - | - |
| Profit Margin | - | - | -13.38 | - | - | - |
| EBITDA | -37.57 Million | -34.22 Million | -33.32 Million | - | -29.45 Million | -24.87 Million |
| Earnings Before Tax Margin | - | - | -15.04 | - | - | - |
GTLL
ARHS
UMIYA
CTKB
KHADIM
SULA